OsteoporosisSTARKNCT03154684
Spitex-SpiTal-Autonomie-Reha-Kraft
A study testing STARK intervention in people with Osteoporosis and Frailty, run by University of Zurich at 1 site in Switzerland.
Trial summary
The primary purpose of this study is to test if the STARK comprehensive autonomy health care package improves lower extremity function over time at 6 weeks, 3, 6 and 12 months after hip or pelvis fracture compared to the standard of care. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Osteoporosis, Frailty, Hip Fractures
- What is being tested?
- STARK intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteSwitzerland
- Study dates
- 5 May 2017to 15 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Community-dwelling prior to the hip fracture event
- Living alone or with a partner/family member
- Living in the city of Zurich
- age 70+
- Acute hip or pelvis fracture after minimal trauma (resulting from a fall occurring from a standard height and without the involvement of others or a vehicle)
- Living at home without or with minimal (i.e. no more than 1x/day) support from the Spitex (ambulant nursing service) before the hip fracture
Show all 9Show fewer
- Participant is mentally competent (judicious) based on the treating physicians' opinion at the screening visit.
- Inpatient rehabilitation or inpatient transitional care at a nursing home or ambulatory standard of care
- The participant understands the study procedures and voluntarily agree to participate in the study and comply with all its procedures by giving written informed consent
Who cannot join
- Patients who are expected to return home without help (i.e. no more care than Spitex 1x/day or physiotherapy 2x/week needed) directly after acute care are excluded.
- Conservative treatment of acute hip fracture or surgical treatment that does not allow full weight bearing after surgery
- Currently under cancer treatment or has active cancer (except for non-melanoma skin cancer)
- Major visual or hearing impairment (visual and/or hearing aids are allowed) or other serious illness that would preclude participation
- 24-hour nursing care need as this cannot be offered within the STARK package
- Mobility impairment that precludes return to own apartment
Show all 10Show fewer
- Planned nursing home admission after acute hospital stay
- Current participation in another clinical trial, or plans of such participation in the next 12 months (corresponding to the study duration)
- Inability to read and/or speak German to an extent necessary to understand instructions and participate in the study
- Unwilling to forego any additional vitamin D supplementation (bolus or regular intake).
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Dept. of Geriatrics and Aging Research, University of Zurich / Geriatric Clinic University Hospital Zurich
Zurich, Canton of Zurich, 8037
About this study
Official title: Efficacy of the STARK Comprehensive Autonomy Health Care Package in Functional Recovery After a Hip Fracture: A Randomized Controlled Trial
The primary purpose of this study is to test if the STARK comprehensive autonomy health care package improves lower extremity function over time at 6 weeks, 3, 6 and 12 months after hip or pelvis fracture compared to the standard of care.
Read the detailed description
Hip fractures are the most frequent and most severe fractures among seniors age 75 and older and they have severe consequences: After a hip fracture, 50% of older persons have permanent functional disabilities, 15-30% require long-term nursing home care, and 10-20% die within one year. Besides the personal burden, hip fractures account for substantial increasing health care expenses. Given the high prevalence, severity and cost of hip fractures, novel care concepts such as STARK are urgently needed to support functionality and autonomy of hip fracture patients - especially in for the first year after the fracture
The STARK Intervention is a new care concept for hip fracture patients, which was developed based on prior evidence from clinical trials performed at the Centre on Aging and Mobility at the University of Zurich and important interdisciplinary clinical expertise collected at the Geriatric Trauma Centre at the University Hospital Zurich, the Spitex Zürich, the Dept. of Geriatrics at the University Hospital Zurich, and the Federal Department of Health at the City of Zurich (Gesundheits- und Umweltsdepartement).
The aim of the STARK intervention is to enable hip fracture patient to return to their home directly after discharge from acute care by providing a high-quality care concept provided by an interdisciplinary team bridging acute Geriatric Care at the University Hospital and Spitex services (ambulant nursing service at home).
With this pilot study, the investigators want to test if the STARK comprehensive autonomy care package improves lower extremity function in the first year after a hip fracture compared to standard of care. Most important secondary outcomes are rate of falls, health care utilization, re-hospitalization and nursing home admission, as well as quality of life, cognitive function, bone mineral density and muscle mass in senior hip fracture patients.
This study will include 20 community-dwelling men and women aged 70+ who are hospitalized at the University Hospital Zurich or City Hospital Waid due to an acute hip or pelvis fracture and who are not capable to return home without help.
This is a randomized controlled pilot trial with two parallel groups including a control group receiving standard of care (inpatient rehabilitation or home-based or inpatient transitional nursing care) and an intervention group receiving the STARK comprehensive autonomy health care package. The STARK comprehensive autonomy health care package consists on one hand of the STARK-Spitex who will support the participants during the first three months at home and on the other hand of a secondary prevention program including home exercise (3x/week), protein enriched food preparation (20 g whey protein/day), motivation and recommendation for vitamin D supplementation(2000 IE/day), calcium intake and physical activity. The intervention starts already during acute care and involves a multidisciplinary team of geriatricians, nurses and Spitex who assess the care and utilities needs of the patient. Each study participant will undergo 5 clinical visits (at baseline, after 6 weeks, 3 months, 6 months, and 12 months). Between clinical visits, participants will be contacted by phone every month.
The STARK comprehensive autonomy health care package can contribute to a faster and sustainable recovery of autonomy after a hip fracture in seniors and might help to lower direct and indirect health care costs by reducing the number of re-hospitalization due to fall-associated injuries.
- Conditions
- Osteoporosis, Frailty, Hip Fractures
- Being tested
- STARK intervention, Standard of Care
- Keywords
- Autonomy, Rehabilitation, Falls, Quality of life, Senior
- Medical subject headings
- Osteoporosis, Frailty, Hip Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
STARK interventionOther
The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;
- Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care
- Inspection of the environment at the patient's home
- Care and autonomy support
- Social life support
- Secondary prevention strategies:
- Home exercise program (3x/weeks)
- Protein enriched food preparation (20g whey protein/day)
- Support to take vitamin D supplementation (2000 IU/day)
- Recommendation and support to eat calcium rich foods
- Motivation to be physically active
Standard of CareOther
Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
| Study group | Role | What they receive |
|---|---|---|
| STARK intervention | Active comparator | New care concept for hip fracture patients Receives: Other: STARK intervention |
| Standard Care | Other | Swiss standard of care for hip fracture patients Receives: Other: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lower extremity function
Lower extremity function will be measured by the Short Physical Performance Battery (SPPB)
Measured: 12 months
Secondary outcomes (17)
Gait speed
Gait speed will be obtained from the SPPB.
Measured: 12 months
Gait speed
Gait speed will be assessed by a 400 m walk test.
Measured: 12 months
Grip strength
Hand grip strength will be measured using a Martin Vigorimeter.
Measured: 12 months
Repeated sit-to-stand
Repeated chair stand test will be obtained from the SPPB.
Measured: 12 months
Rate of falls
Rate of falls will be assessed by a monthly phone call.
Measured: 12 months
Health care utilization
Health care utilization will be assessed using the health care utilization questionnaire.
Measured: 12 months
Number of re-hospitalizations
All hospitalizations will be documented as part of the safety documentation(SAE).
Measured: 12 months
Number of nursing home admissions
All nursing home admissions will be documented.
Measured: 12 months
Adherence to preventive strategies
Adherence will be documented by the Spitex staff.
Measured: 3 months
Adherence to preventive strategies
Adherence will be documented by an adherence questionnaire.
Measured: 12 months
Quality of life
Quality of life will be assessed by the RAND SF-36 questionnaire.
Measured: 12 months
Quality of life
Quality of life will be assessed by the EuroQol (EQ-5D-3L) questionnaire.
Measured: 12 months
Cognitive function
Cognitive function will be assessed by the MoCA.
Measured: 12 months
Cognitive function
Cognitive function will be assessed by the MMSE.
Measured: 12 months
Appendicular muscle mass
Appendicular muscle mass will be assessed by dual energy X-ray absorptiometry.
Measured: 12 months
Bone mineral density
Bone mineral density will be assessed by dual energy X-ray absorptiometry.
Measured: 12 months
Activities of daily living
Activities of daily living will be assessed by questionnaire (PROMIS-HAQ)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2017
- Study start5 May 2017
- Primary completion15 Aug 2021
- Study completion15 Aug 2021
Why it stopped: Insufficient Recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoporosisStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Collaborators
- Spitex Zürich, Switzerland, City of Zurich, Switzerland, University Hospital, Zürich, University of Applied Sciences of Western Switzerland, Ebnet Stiftung, Switzerland
- Responsible party
- Sponsor
- Investigators
- Heike Bischoff-Ferrari, Prof., Principal investigator, Zentrum Alter und Mobilität
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03154684
- Sponsor's protocol ID
- 2016-01820
- Other IDs
- 2016
- Acronym
- STARK
- Status last verified
- Aug 2021
- First submitted
- 4 May 2017
- Last updated
- 1 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of the STARK Comprehensive Autonomy Health Care Package in Functional Recovery After a Hip Fracture: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT03154684
- Acronym / sponsor ID
- STARK / 2016-01820
- Conditions
- Osteoporosis, Frailty, Hip Fractures
- Keywords
- Autonomy, Rehabilitation, Falls, Quality of life, Senior
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Insufficient Recruitment
- Enrolment
- 5 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Collaborators
- Spitex Zürich, Switzerland, City of Zurich, Switzerland, University Hospital, Zürich, University of Applied Sciences of Western Switzerland, Ebnet Stiftung, Switzerland
- Study start
- 5 May 2017 (actual)
- Primary completion
- 15 Aug 2021 (actual)
- Study completion
- 15 Aug 2021 (actual)
- First posted
- 16 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to test if the STARK comprehensive autonomy health care package improves lower extremity function over time at 6 weeks, 3, 6 and 12 months after hip or pelvis fracture compared to the standard of care.
Detailed description
Hip fractures are the most frequent and most severe fractures among seniors age 75 and older and they have severe consequences: After a hip fracture, 50% of older persons have permanent functional disabilities, 15-30% require long-term nursing home care, and 10-20% die within one year. Besides the personal burden, hip fractures account for substantial increasing health care expenses. Given the high prevalence, severity and cost of hip fractures, novel care concepts such as STARK are urgently needed to support functionality and autonomy of hip fracture patients - especially in for the first year after the fracture
The STARK Intervention is a new care concept for hip fracture patients, which was developed based on prior evidence from clinical trials performed at the Centre on Aging and Mobility at the University of Zurich and important interdisciplinary clinical expertise collected at the Geriatric Trauma Centre at the University Hospital Zurich, the Spitex Zürich, the Dept. of Geriatrics at the University Hospital Zurich, and the Federal Department of Health at the City of Zurich (Gesundheits- und Umweltsdepartement).
The aim of the STARK intervention is to enable hip fracture patient to return to their home directly after discharge from acute care by providing a high-quality care concept provided by an interdisciplinary team bridging acute Geriatric Care at the University Hospital and Spitex services (ambulant nursing service at home).
With this pilot study, the investigators want to test if the STARK comprehensive autonomy care package improves lower extremity function in the first year after a hip fracture compared to standard of care. Most important secondary outcomes are rate of falls, health care utilization, re-hospitalization and nursing home admission, as well as quality of life, cognitive function, bone mineral density and muscle mass in senior hip fracture patients.
This study will include 20 community-dwelling men and women aged 70+ who are hospitalized at the University Hospital Zurich or City Hospital Waid due to an acute hip or pelvis fracture and who are not capable to return home without help.
This is a randomized controlled pilot trial with two parallel groups including a control group receiving standard of care (inpatient rehabilitation or home-based or inpatient transitional nursing care) and an intervention group receiving the STARK comprehensive autonomy health care package. The STARK comprehensive autonomy health care package consists on one hand of the STARK-Spitex who will support the participants during the first three months at home and on the other hand of a secondary prevention program including home exercise (3x/week), protein enriched food preparation (20 g whey protein/day), motivation and recommendation for vitamin D supplementation(2000 IE/day), calcium intake and physical activity. The intervention starts already during acute care and involves a multidisciplinary team of geriatricians, nurses and Spitex who assess the care and utilities needs of the patient. Each study participant will undergo 5 clinical visits (at baseline, after 6 weeks, 3 months, 6 months, and 12 months). Between clinical visits, participants will be contacted by phone every month.
The STARK comprehensive autonomy health care package can contribute to a faster and sustainable recovery of autonomy after a hip fracture in seniors and might help to lower direct and indirect health care costs by reducing the number of re-hospitalization due to fall-associated injuries.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| STARK intervention | Active comparator | Other: STARK interventionNew care concept for hip fracture patients |
| Standard Care | Other | Other: Standard of CareSwiss standard of care for hip fracture patients |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (9 listed)
- Community-dwelling prior to the hip fracture event
- Living alone or with a partner/family member
- Living in the city of Zurich
- age 70+
- Acute hip or pelvis fracture after minimal trauma (resulting from a fall occurring from a standard height and without the involvement of others or a vehicle)
Key exclusion criteria (10 listed)
- Patients who are expected to return home without help (i.e. no more care than Spitex 1x/day or physiotherapy 2x/week needed) directly after acute care are excluded.
- Conservative treatment of acute hip fracture or surgical treatment that does not allow full weight bearing after surgery
- Currently under cancer treatment or has active cancer (except for non-melanoma skin cancer)
- Major visual or hearing impairment (visual and/or hearing aids are allowed) or other serious illness that would preclude participation
- 24-hour nursing care need as this cannot be offered within the STARK package
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| STARK interventionThe STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services; * Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care * Inspection of the environment at the patient's home * Care and autonomy support * Social life support * Secondary prevention strategies: * Home exercise program (3x/weeks) * Protein enriched food preparation (20g whey protein/day) * Support to take vitamin D supplementation (2000 IU/day) * Recommendation and support to eat calcium rich foods * Motivation to be physically active | Other | STARK intervention |
| Standard of CareStandard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care | Other | Standard Care |
Primary outcome
Lower extremity function
Time frame: 12 months
Lower extremity function will be measured by the Short Physical Performance Battery (SPPB)
17 secondary outcomes
Gait speed
Time frame: 12 months
Gait speed
Time frame: 12 months
Grip strength
Time frame: 12 months
Repeated sit-to-stand
Time frame: 12 months
Rate of falls
Time frame: 12 months
Health care utilization
Time frame: 12 months
Number of re-hospitalizations
Time frame: 12 months
Number of nursing home admissions
Time frame: 12 months
Adherence to preventive strategies
Time frame: 3 months
Adherence to preventive strategies
Time frame: 12 months
Quality of life
Time frame: 12 months
Quality of life
Time frame: 12 months
Cognitive function
Time frame: 12 months
Cognitive function
Time frame: 12 months
Appendicular muscle mass
Time frame: 12 months
Bone mineral density
Time frame: 12 months
Activities of daily living
Time frame: 12 months
Results and safety
The study was stopped early (reason given: Insufficient Recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2021.
- Individual participant dataSharing planned: No
Related trials for Osteoporosis
RecruitingObservational study
A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.
Vertebra Compression Fracture
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
Not yet recruitingPhase 4
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Postmenopausal Osteoporosis
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
RecruitingObservational study
Assessment and Comparison of Osteoporosis Risk Factors After Stroke
Stroke, Osteoporosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Heike Bischoff-Ferrari, Prof. principal investigator
Zentrum Alter und Mobilität
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing STARK intervention in people with Osteoporosis and Frailty, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Insufficient Recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lower extremity function (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2021.